Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2025-01-29 00:00:00 ET · period of report 2025-01-27 · accession 0001735276-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-01-29 | 2025-01-27 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | M - OptEx | $88.95 | +48.9K | 39.6K | New | +$4.35M |
| D | 2025-01-29 | 2025-01-27 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | S - Sale+OE | $285.00 | -52.6K | 12.0K | -81% | -$14.99M |
| DM | 2025-01-29 | 2025-01-27 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | M - OptEx | $0.00 | -48.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-27 | M | A | 25,000 | $88.95 | 64,581 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-27 | S | D | 52,592 | $285.00 | 11,989 | D | — | — | |
| 3 | Common | Common Stock | 2025-01-27 | M | A | 23,876 | $88.95 | 39,581 | D | — | — | |
| 4 | Derivative | Performance Stock Option 2015 (right to buy) | 2025-01-27 | M | D | 25,000 | $0.00 | 0 | D | $88.95 · 2019-08-06 to 2025-12-18 | 25,000 Common Stock | (F4) This stock option was fully vested and exercisable as of August 6, 2019. |
| 5 | Derivative | Stock Option (right to buy) | 2025-01-27 | M | D | 23,876 | $0.00 | 0 | D | $88.95 · 2019-12-18 to 2025-12-18 | 23,876 Common Stock | (F5) This stock option was fully vested and exercisable as of December 18, 2019. |